Tecfidera Approved for the Long-Term Treatment of MS
The United States Food and Drug Administration (FDA) announced that it has approved Tecfidera™ (dimethyl fumarate or DMF, formerly known as BG-12) for the treatment of relapsing forms of multiple sclerosis (MS). This is the 10th drug to be approved as a disease-modifying therapy (DMT) for the long-term treatment of multiple sclerosis (MS). Tecfidera is administered orally (by mouth) and is the third oral DMT approved for MS.
As with all of the approved DMTs for MS, Tecfidera is not a cure, but does slow MS disease activity. It reduces the number and severity of MS relapses (or symptom flare-ups) while reducing disease activity as seen on magnetic resonance imaging (MRI) scans — by reducing the number and size of brain lesions (areas of inflammation). Additionally, Tecfidera slowed the progression of sustained disability (in one of two large Phase III trials).